Compare MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MicroSectors FANG and Innovation 3X Leveraged ETN vs Regeneron Pharmaceuticals Inc — how do they compare? MicroSectors FANG and Innovation 3X Leveraged ETN trades at $32.41, while Regeneron Pharmaceuticals Inc trades at $791.9 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.47% dividend while MicroSectors FANG and Innovation 3X Leveraged ETN pays none. Which is the better fit depends on your goals.
| FNGU | REGN | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $36.15 | $812.27 |
52-Week Low | $13.73 | $555.51 |
Market Cap | — | $82.06B |
Enterprise Value | — | $76.77B |
Dividend Yield | — | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNGU, a 3X leveraged ETN tracking the FANG+ Index, trades at $32.53, down 3.47% on the day. Technical indicators show a bullish trend with moving averages supporting upside, though RSI levels suggest overbought conditions. Recent news highlights extreme volatility, with a 16% single-session loss reported on June 5, 2026, underscoring the product's leveraged risk.
The outlook for FNGU hinges on continued strength in mega-cap tech stocks, but risks are elevated due to leverage decay and market volatility. Investors face potential for amplified gains or losses, with sentiment cautious amid recent sharp declines. Careful risk management is essential given the ETN's structure.
Regeneron Pharmaceuticals (REGN) trades at $808.05, up 3.02% today, with strong technical momentum and bullish moving averages. The company shows robust fundamentals: Q2 2026 EPS of $14.29 beat expectations by over 40%, revenue grew to $14.34B in 2025, and profit margins exceed 27%. However, RSI levels above 95 indicate overbought conditions, and the stock faces headwinds from multiple class-action lawsuits related to clinical trial disclosures.
Outlook remains positive due to earnings beats and product strength in Eylea HD and Dupixent, but legal overhangs and high valuation multiples pose near-term risks. Analysts maintain a Buy consensus with a $756.93 price target, suggesting cautious optimism amid legal scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About MicroSectors FANG and Innovation 3X Leveraged ETN
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
